Our Pricing

Wegovy vs Mounjaro: Clinical Evidence Comparison UK

Published on: June 03, 2026

When evaluating wegovy vs mounjaro clinical evidence uk, understanding the landmark trials behind each medication helps UK patients make informed decisions. Both treatments are MHRA-licensed GLP-1 receptor agonists, but their clinical profiles, mechanisms, and trial outcomes differ significantly—and those differences matter when choosing the right weight management approach with your UK prescriber.

Understanding the Mechanisms: Dual vs Single Receptor Activation

Mounjaro (tirzepatide) represents the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK, activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways simultaneously [1]. This dual action enhances insulin secretion, suppresses glucagon release, and prolongs gastric emptying more comprehensively than single-pathway agents.

Wegovy (semaglutide) works as a selective GLP-1 receptor agonist, targeting only the GLP-1 pathway to regulate appetite and glucose metabolism [2]. While highly effective on its own, semaglutide's single-receptor mechanism produces different metabolic effects compared to tirzepatide's dual approach, which is reflected in their respective clinical trial outcomes.

SURPASS Trials: Mounjaro's Clinical Evidence Base

The SURPASS programme comprises five Phase 3 trials evaluating tirzepatide across diverse patient populations. In SURPASS-2, which directly compared tirzepatide to semaglutide 1mg, patients receiving the highest tirzepatide dose (15mg) achieved an average 15.7% body weight reduction at 40 weeks, compared to 9.6% with semaglutide [1]. This head-to-head comparison demonstrated tirzepatide's superior weight loss efficacy in a randomised controlled setting.

SURPASS-3 examined tirzepatide in patients with type 2 diabetes over 72 weeks, where the 15mg dose produced an average 22.5% weight reduction—the highest sustained weight loss observed in any obesity pharmacotherapy trial to date [1]. Importantly, 91% of participants on the maximum dose achieved at least 5% weight loss, and 57% reached the 20% threshold typically associated with bariatric surgery outcomes.

Across the SURPASS programme, tirzepatide demonstrated consistent dose-dependent weight loss, with the 5mg, 10mg, and 15mg doses producing progressively greater reductions. Safety profiles were generally comparable to other GLP-1 therapies, with gastrointestinal side effects being the most common adverse events reported [1].

Real-World Implications of SURPASS Data

The SURPASS findings translate to meaningful clinical outcomes for UK patients. Achieving 20%+ body weight reduction can significantly improve obesity-related comorbidities including type 2 diabetes, hypertension, and obstructive sleep apnoea. Your UK prescriber will consider these trial results alongside your individual health profile when determining whether Mounjaro is appropriate for your weight management goals.

STEP Trials: Wegovy's Clinical Foundation

The STEP clinical programme evaluated semaglutide 2.4mg (marketed as Wegovy) across four major trials involving over 4,500 participants. In STEP 1, the pivotal 68-week trial in adults with obesity or overweight, participants receiving semaglutide achieved an average 14.9% body weight reduction compared to 2.4% with placebo [2]. This represented a clinically significant improvement in weight management outcomes.

STEP 2 specifically examined semaglutide in patients with type 2 diabetes, demonstrating an average 9.6% weight loss over 68 weeks—lower than in non-diabetic populations but still substantially greater than placebo [2]. This trial established semaglutide's efficacy across different metabolic profiles, though the presence of diabetes appeared to moderate weight loss responses.

Long-term data from STEP 5 extended follow-up to 104 weeks, where participants maintained an average 15.2% weight reduction, demonstrating semaglutide's durability as a chronic weight management therapy [2]. Gastrointestinal side effects were the primary tolerability concern, typically mild to moderate and diminishing over time.

Wegovy's Clinical Profile in UK Practice

The STEP programme established semaglutide as a highly effective weight management option, with consistent results across diverse patient groups. NICE guidance recognises Wegovy for adults with at least one weight-related comorbidity and a BMI ≥35 kg/m² (or ≥32.5 kg/m² for certain ethnic groups), making it an accessible option within UK prescribing frameworks when clinically appropriate.

Direct Comparison: Wegovy vs Mounjaro Clinical Outcomes

When comparing wegovy vs mounjaro clinical evidence uk directly, SURPASS-2 provides the only head-to-head trial data. In this 40-week study, tirzepatide 15mg produced 6.1 percentage points greater weight loss than semaglutide 1mg (15.7% vs 9.6%) [1]. However, it's important to note this compared tirzepatide to semaglutide 1mg—not the 2.4mg Wegovy dose used for weight management.

Indirect comparisons across trials suggest tirzepatide's highest doses may produce 3-7 percentage points more weight loss than semaglutide 2.4mg, though cross-trial comparisons have inherent limitations due to different patient populations, trial designs, and follow-up durations. Both medications demonstrate robust efficacy well beyond lifestyle interventions alone, with weight loss typically plateauing between 60-72 weeks.

Side effect profiles are broadly similar between the two treatments, with nausea, diarrhoea, and constipation being the most frequently reported adverse events [1][2]. Discontinuation rates due to gastrointestinal side effects were comparable in both trial programmes, ranging from 4-7% of participants. Your UK prescriber will assess your tolerance and response over the initial weeks of treatment.

Prescribing Considerations: Which Treatment for Which Patient?

UK prescribers consider multiple factors beyond raw weight loss percentages when recommending between Mounjaro and Wegovy. Patient-specific variables including diabetes status, cardiovascular risk profile, previous medication responses, and individual tolerability all influence treatment selection. Both medications require once-weekly subcutaneous injection, making adherence profiles similar.

Cost considerations also play a role in UK prescribing decisions. At Cured Pharmacy, Mounjaro starts from £124.99 while Wegovy is available from £135.00 subject to clinical assessment and prescriber approval. Your UK prescriber will discuss which treatment aligns with both your clinical needs and practical considerations during your free online consultation.

For patients with type 2 diabetes, Mounjaro's dual GIP/GLP-1 mechanism may offer additional glycaemic benefits beyond weight loss, as demonstrated in the SURPASS trials [1]. Conversely, patients seeking an established treatment with extensive real-world use may prefer Wegovy's longer market presence and broader prescribing experience across UK clinical practice.

Starting Treatment: What to Expect

Both medications follow dose-escalation protocols to minimise gastrointestinal side effects. Mounjaro typically starts at 2.5mg weekly, increasing every four weeks, whilst Wegovy begins at 0.25mg with monthly dose increases. Your UK prescriber will monitor your progress and adjust dosing based on your response and tolerability. All prescription weight loss treatments at Cured Pharmacy require completion of a clinical assessment by a UK-registered prescriber before dispensing.

Beyond Weight Loss: Cardiometabolic Benefits in Clinical Trials

Both STEP and SURPASS trials documented improvements in cardiometabolic markers beyond weight reduction. In STEP 1, semaglutide significantly reduced systolic blood pressure (average 6.2 mmHg decrease), improved lipid profiles, and decreased inflammatory markers including C-reactive protein [2]. These changes suggest cardiovascular benefits independent of weight loss alone.

SURPASS trials similarly demonstrated cardiometabolic improvements with tirzepatide, including HbA1c reductions of up to 2.4% in patients with type 2 diabetes, alongside improvements in blood pressure, triglycerides, and HDL cholesterol [1]. The SELECT cardiovascular outcomes trial for semaglutide has shown significant reduction in major adverse cardiovascular events, whilst tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) results are awaited.

For UK patients with obesity-related comorbidities, these secondary benefits may be as clinically significant as weight loss itself. Your prescriber will consider your complete cardiovascular risk profile when recommending treatment, as both medications offer potential benefits beyond the number on the scale.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and are not guaranteed. Clinical trial data represents average outcomes and individual responses may differ.